Cargando…
Multi-omics analysis defines highly refractory RAS burdened immature subgroup of infant acute lymphoblastic leukemia
KMT2A-rearranged infant acute lymphoblastic leukemia (ALL) represents the most refractory type of childhood leukemia. To uncover the molecular heterogeneity of this disease, we perform RNA sequencing, methylation array analysis, whole exome and targeted deep sequencing on 84 infants with KMT2A-rearr...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9427775/ https://www.ncbi.nlm.nih.gov/pubmed/36042201 http://dx.doi.org/10.1038/s41467-022-32266-4 |
_version_ | 1784778970526384128 |
---|---|
author | Isobe, Tomoya Takagi, Masatoshi Sato-Otsubo, Aiko Nishimura, Akira Nagae, Genta Yamagishi, Chika Tamura, Moe Tanaka, Yosuke Asada, Shuhei Takeda, Reina Tsuchiya, Akiho Wang, Xiaonan Yoshida, Kenichi Nannya, Yasuhito Ueno, Hiroo Akazawa, Ryo Kato, Itaru Mikami, Takashi Watanabe, Kentaro Sekiguchi, Masahiro Seki, Masafumi Kimura, Shunsuke Hiwatari, Mitsuteru Kato, Motohiro Fukuda, Shiro Tatsuno, Kenji Tsutsumi, Shuichi Kanai, Akinori Inaba, Toshiya Shiozawa, Yusuke Shiraishi, Yuichi Chiba, Kenichi Tanaka, Hiroko Kotecha, Rishi S. Cruickshank, Mark N. Ishikawa, Fumihiko Morio, Tomohiro Eguchi, Mariko Deguchi, Takao Kiyokawa, Nobutaka Arakawa, Yuki Koh, Katsuyoshi Aoki, Yuki Ishihara, Takashi Tomizawa, Daisuke Miyamura, Takako Ishii, Eiichi Mizutani, Shuki Wilson, Nicola K. Göttgens, Berthold Miyano, Satoru Kitamura, Toshio Goyama, Susumu Yokoyama, Akihiko Aburatani, Hiroyuki Ogawa, Seishi Takita, Junko |
author_facet | Isobe, Tomoya Takagi, Masatoshi Sato-Otsubo, Aiko Nishimura, Akira Nagae, Genta Yamagishi, Chika Tamura, Moe Tanaka, Yosuke Asada, Shuhei Takeda, Reina Tsuchiya, Akiho Wang, Xiaonan Yoshida, Kenichi Nannya, Yasuhito Ueno, Hiroo Akazawa, Ryo Kato, Itaru Mikami, Takashi Watanabe, Kentaro Sekiguchi, Masahiro Seki, Masafumi Kimura, Shunsuke Hiwatari, Mitsuteru Kato, Motohiro Fukuda, Shiro Tatsuno, Kenji Tsutsumi, Shuichi Kanai, Akinori Inaba, Toshiya Shiozawa, Yusuke Shiraishi, Yuichi Chiba, Kenichi Tanaka, Hiroko Kotecha, Rishi S. Cruickshank, Mark N. Ishikawa, Fumihiko Morio, Tomohiro Eguchi, Mariko Deguchi, Takao Kiyokawa, Nobutaka Arakawa, Yuki Koh, Katsuyoshi Aoki, Yuki Ishihara, Takashi Tomizawa, Daisuke Miyamura, Takako Ishii, Eiichi Mizutani, Shuki Wilson, Nicola K. Göttgens, Berthold Miyano, Satoru Kitamura, Toshio Goyama, Susumu Yokoyama, Akihiko Aburatani, Hiroyuki Ogawa, Seishi Takita, Junko |
author_sort | Isobe, Tomoya |
collection | PubMed |
description | KMT2A-rearranged infant acute lymphoblastic leukemia (ALL) represents the most refractory type of childhood leukemia. To uncover the molecular heterogeneity of this disease, we perform RNA sequencing, methylation array analysis, whole exome and targeted deep sequencing on 84 infants with KMT2A-rearranged leukemia. Our multi-omics clustering followed by single-sample and single-cell inference of hematopoietic differentiation establishes five robust integrative clusters (ICs) with different master transcription factors, fusion partners and corresponding stages of B-lymphopoietic and early hemato-endothelial development: IRX-type differentiated (IC1), IRX-type undifferentiated (IC2), HOXA-type MLLT1 (IC3), HOXA-type MLLT3 (IC4), and HOXA-type AFF1 (IC5). Importantly, our deep mutational analysis reveals that the number of RAS pathway mutations predicts prognosis and that the most refractory subgroup of IC2 possesses 100% frequency and the heaviest burden of RAS pathway mutations. Our findings highlight the previously under-appreciated intra- and inter-patient heterogeneity of KMT2A-rearranged infant ALL and provide a rationale for the future development of genomics-guided risk stratification and individualized therapy. |
format | Online Article Text |
id | pubmed-9427775 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-94277752022-09-01 Multi-omics analysis defines highly refractory RAS burdened immature subgroup of infant acute lymphoblastic leukemia Isobe, Tomoya Takagi, Masatoshi Sato-Otsubo, Aiko Nishimura, Akira Nagae, Genta Yamagishi, Chika Tamura, Moe Tanaka, Yosuke Asada, Shuhei Takeda, Reina Tsuchiya, Akiho Wang, Xiaonan Yoshida, Kenichi Nannya, Yasuhito Ueno, Hiroo Akazawa, Ryo Kato, Itaru Mikami, Takashi Watanabe, Kentaro Sekiguchi, Masahiro Seki, Masafumi Kimura, Shunsuke Hiwatari, Mitsuteru Kato, Motohiro Fukuda, Shiro Tatsuno, Kenji Tsutsumi, Shuichi Kanai, Akinori Inaba, Toshiya Shiozawa, Yusuke Shiraishi, Yuichi Chiba, Kenichi Tanaka, Hiroko Kotecha, Rishi S. Cruickshank, Mark N. Ishikawa, Fumihiko Morio, Tomohiro Eguchi, Mariko Deguchi, Takao Kiyokawa, Nobutaka Arakawa, Yuki Koh, Katsuyoshi Aoki, Yuki Ishihara, Takashi Tomizawa, Daisuke Miyamura, Takako Ishii, Eiichi Mizutani, Shuki Wilson, Nicola K. Göttgens, Berthold Miyano, Satoru Kitamura, Toshio Goyama, Susumu Yokoyama, Akihiko Aburatani, Hiroyuki Ogawa, Seishi Takita, Junko Nat Commun Article KMT2A-rearranged infant acute lymphoblastic leukemia (ALL) represents the most refractory type of childhood leukemia. To uncover the molecular heterogeneity of this disease, we perform RNA sequencing, methylation array analysis, whole exome and targeted deep sequencing on 84 infants with KMT2A-rearranged leukemia. Our multi-omics clustering followed by single-sample and single-cell inference of hematopoietic differentiation establishes five robust integrative clusters (ICs) with different master transcription factors, fusion partners and corresponding stages of B-lymphopoietic and early hemato-endothelial development: IRX-type differentiated (IC1), IRX-type undifferentiated (IC2), HOXA-type MLLT1 (IC3), HOXA-type MLLT3 (IC4), and HOXA-type AFF1 (IC5). Importantly, our deep mutational analysis reveals that the number of RAS pathway mutations predicts prognosis and that the most refractory subgroup of IC2 possesses 100% frequency and the heaviest burden of RAS pathway mutations. Our findings highlight the previously under-appreciated intra- and inter-patient heterogeneity of KMT2A-rearranged infant ALL and provide a rationale for the future development of genomics-guided risk stratification and individualized therapy. Nature Publishing Group UK 2022-08-30 /pmc/articles/PMC9427775/ /pubmed/36042201 http://dx.doi.org/10.1038/s41467-022-32266-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Isobe, Tomoya Takagi, Masatoshi Sato-Otsubo, Aiko Nishimura, Akira Nagae, Genta Yamagishi, Chika Tamura, Moe Tanaka, Yosuke Asada, Shuhei Takeda, Reina Tsuchiya, Akiho Wang, Xiaonan Yoshida, Kenichi Nannya, Yasuhito Ueno, Hiroo Akazawa, Ryo Kato, Itaru Mikami, Takashi Watanabe, Kentaro Sekiguchi, Masahiro Seki, Masafumi Kimura, Shunsuke Hiwatari, Mitsuteru Kato, Motohiro Fukuda, Shiro Tatsuno, Kenji Tsutsumi, Shuichi Kanai, Akinori Inaba, Toshiya Shiozawa, Yusuke Shiraishi, Yuichi Chiba, Kenichi Tanaka, Hiroko Kotecha, Rishi S. Cruickshank, Mark N. Ishikawa, Fumihiko Morio, Tomohiro Eguchi, Mariko Deguchi, Takao Kiyokawa, Nobutaka Arakawa, Yuki Koh, Katsuyoshi Aoki, Yuki Ishihara, Takashi Tomizawa, Daisuke Miyamura, Takako Ishii, Eiichi Mizutani, Shuki Wilson, Nicola K. Göttgens, Berthold Miyano, Satoru Kitamura, Toshio Goyama, Susumu Yokoyama, Akihiko Aburatani, Hiroyuki Ogawa, Seishi Takita, Junko Multi-omics analysis defines highly refractory RAS burdened immature subgroup of infant acute lymphoblastic leukemia |
title | Multi-omics analysis defines highly refractory RAS burdened immature subgroup of infant acute lymphoblastic leukemia |
title_full | Multi-omics analysis defines highly refractory RAS burdened immature subgroup of infant acute lymphoblastic leukemia |
title_fullStr | Multi-omics analysis defines highly refractory RAS burdened immature subgroup of infant acute lymphoblastic leukemia |
title_full_unstemmed | Multi-omics analysis defines highly refractory RAS burdened immature subgroup of infant acute lymphoblastic leukemia |
title_short | Multi-omics analysis defines highly refractory RAS burdened immature subgroup of infant acute lymphoblastic leukemia |
title_sort | multi-omics analysis defines highly refractory ras burdened immature subgroup of infant acute lymphoblastic leukemia |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9427775/ https://www.ncbi.nlm.nih.gov/pubmed/36042201 http://dx.doi.org/10.1038/s41467-022-32266-4 |
work_keys_str_mv | AT isobetomoya multiomicsanalysisdefineshighlyrefractoryrasburdenedimmaturesubgroupofinfantacutelymphoblasticleukemia AT takagimasatoshi multiomicsanalysisdefineshighlyrefractoryrasburdenedimmaturesubgroupofinfantacutelymphoblasticleukemia AT satootsuboaiko multiomicsanalysisdefineshighlyrefractoryrasburdenedimmaturesubgroupofinfantacutelymphoblasticleukemia AT nishimuraakira multiomicsanalysisdefineshighlyrefractoryrasburdenedimmaturesubgroupofinfantacutelymphoblasticleukemia AT nagaegenta multiomicsanalysisdefineshighlyrefractoryrasburdenedimmaturesubgroupofinfantacutelymphoblasticleukemia AT yamagishichika multiomicsanalysisdefineshighlyrefractoryrasburdenedimmaturesubgroupofinfantacutelymphoblasticleukemia AT tamuramoe multiomicsanalysisdefineshighlyrefractoryrasburdenedimmaturesubgroupofinfantacutelymphoblasticleukemia AT tanakayosuke multiomicsanalysisdefineshighlyrefractoryrasburdenedimmaturesubgroupofinfantacutelymphoblasticleukemia AT asadashuhei multiomicsanalysisdefineshighlyrefractoryrasburdenedimmaturesubgroupofinfantacutelymphoblasticleukemia AT takedareina multiomicsanalysisdefineshighlyrefractoryrasburdenedimmaturesubgroupofinfantacutelymphoblasticleukemia AT tsuchiyaakiho multiomicsanalysisdefineshighlyrefractoryrasburdenedimmaturesubgroupofinfantacutelymphoblasticleukemia AT wangxiaonan multiomicsanalysisdefineshighlyrefractoryrasburdenedimmaturesubgroupofinfantacutelymphoblasticleukemia AT yoshidakenichi multiomicsanalysisdefineshighlyrefractoryrasburdenedimmaturesubgroupofinfantacutelymphoblasticleukemia AT nannyayasuhito multiomicsanalysisdefineshighlyrefractoryrasburdenedimmaturesubgroupofinfantacutelymphoblasticleukemia AT uenohiroo multiomicsanalysisdefineshighlyrefractoryrasburdenedimmaturesubgroupofinfantacutelymphoblasticleukemia AT akazawaryo multiomicsanalysisdefineshighlyrefractoryrasburdenedimmaturesubgroupofinfantacutelymphoblasticleukemia AT katoitaru multiomicsanalysisdefineshighlyrefractoryrasburdenedimmaturesubgroupofinfantacutelymphoblasticleukemia AT mikamitakashi multiomicsanalysisdefineshighlyrefractoryrasburdenedimmaturesubgroupofinfantacutelymphoblasticleukemia AT watanabekentaro multiomicsanalysisdefineshighlyrefractoryrasburdenedimmaturesubgroupofinfantacutelymphoblasticleukemia AT sekiguchimasahiro multiomicsanalysisdefineshighlyrefractoryrasburdenedimmaturesubgroupofinfantacutelymphoblasticleukemia AT sekimasafumi multiomicsanalysisdefineshighlyrefractoryrasburdenedimmaturesubgroupofinfantacutelymphoblasticleukemia AT kimurashunsuke multiomicsanalysisdefineshighlyrefractoryrasburdenedimmaturesubgroupofinfantacutelymphoblasticleukemia AT hiwatarimitsuteru multiomicsanalysisdefineshighlyrefractoryrasburdenedimmaturesubgroupofinfantacutelymphoblasticleukemia AT katomotohiro multiomicsanalysisdefineshighlyrefractoryrasburdenedimmaturesubgroupofinfantacutelymphoblasticleukemia AT fukudashiro multiomicsanalysisdefineshighlyrefractoryrasburdenedimmaturesubgroupofinfantacutelymphoblasticleukemia AT tatsunokenji multiomicsanalysisdefineshighlyrefractoryrasburdenedimmaturesubgroupofinfantacutelymphoblasticleukemia AT tsutsumishuichi multiomicsanalysisdefineshighlyrefractoryrasburdenedimmaturesubgroupofinfantacutelymphoblasticleukemia AT kanaiakinori multiomicsanalysisdefineshighlyrefractoryrasburdenedimmaturesubgroupofinfantacutelymphoblasticleukemia AT inabatoshiya multiomicsanalysisdefineshighlyrefractoryrasburdenedimmaturesubgroupofinfantacutelymphoblasticleukemia AT shiozawayusuke multiomicsanalysisdefineshighlyrefractoryrasburdenedimmaturesubgroupofinfantacutelymphoblasticleukemia AT shiraishiyuichi multiomicsanalysisdefineshighlyrefractoryrasburdenedimmaturesubgroupofinfantacutelymphoblasticleukemia AT chibakenichi multiomicsanalysisdefineshighlyrefractoryrasburdenedimmaturesubgroupofinfantacutelymphoblasticleukemia AT tanakahiroko multiomicsanalysisdefineshighlyrefractoryrasburdenedimmaturesubgroupofinfantacutelymphoblasticleukemia AT kotecharishis multiomicsanalysisdefineshighlyrefractoryrasburdenedimmaturesubgroupofinfantacutelymphoblasticleukemia AT cruickshankmarkn multiomicsanalysisdefineshighlyrefractoryrasburdenedimmaturesubgroupofinfantacutelymphoblasticleukemia AT ishikawafumihiko multiomicsanalysisdefineshighlyrefractoryrasburdenedimmaturesubgroupofinfantacutelymphoblasticleukemia AT moriotomohiro multiomicsanalysisdefineshighlyrefractoryrasburdenedimmaturesubgroupofinfantacutelymphoblasticleukemia AT eguchimariko multiomicsanalysisdefineshighlyrefractoryrasburdenedimmaturesubgroupofinfantacutelymphoblasticleukemia AT deguchitakao multiomicsanalysisdefineshighlyrefractoryrasburdenedimmaturesubgroupofinfantacutelymphoblasticleukemia AT kiyokawanobutaka multiomicsanalysisdefineshighlyrefractoryrasburdenedimmaturesubgroupofinfantacutelymphoblasticleukemia AT arakawayuki multiomicsanalysisdefineshighlyrefractoryrasburdenedimmaturesubgroupofinfantacutelymphoblasticleukemia AT kohkatsuyoshi multiomicsanalysisdefineshighlyrefractoryrasburdenedimmaturesubgroupofinfantacutelymphoblasticleukemia AT aokiyuki multiomicsanalysisdefineshighlyrefractoryrasburdenedimmaturesubgroupofinfantacutelymphoblasticleukemia AT ishiharatakashi multiomicsanalysisdefineshighlyrefractoryrasburdenedimmaturesubgroupofinfantacutelymphoblasticleukemia AT tomizawadaisuke multiomicsanalysisdefineshighlyrefractoryrasburdenedimmaturesubgroupofinfantacutelymphoblasticleukemia AT miyamuratakako multiomicsanalysisdefineshighlyrefractoryrasburdenedimmaturesubgroupofinfantacutelymphoblasticleukemia AT ishiieiichi multiomicsanalysisdefineshighlyrefractoryrasburdenedimmaturesubgroupofinfantacutelymphoblasticleukemia AT mizutanishuki multiomicsanalysisdefineshighlyrefractoryrasburdenedimmaturesubgroupofinfantacutelymphoblasticleukemia AT wilsonnicolak multiomicsanalysisdefineshighlyrefractoryrasburdenedimmaturesubgroupofinfantacutelymphoblasticleukemia AT gottgensberthold multiomicsanalysisdefineshighlyrefractoryrasburdenedimmaturesubgroupofinfantacutelymphoblasticleukemia AT miyanosatoru multiomicsanalysisdefineshighlyrefractoryrasburdenedimmaturesubgroupofinfantacutelymphoblasticleukemia AT kitamuratoshio multiomicsanalysisdefineshighlyrefractoryrasburdenedimmaturesubgroupofinfantacutelymphoblasticleukemia AT goyamasusumu multiomicsanalysisdefineshighlyrefractoryrasburdenedimmaturesubgroupofinfantacutelymphoblasticleukemia AT yokoyamaakihiko multiomicsanalysisdefineshighlyrefractoryrasburdenedimmaturesubgroupofinfantacutelymphoblasticleukemia AT aburatanihiroyuki multiomicsanalysisdefineshighlyrefractoryrasburdenedimmaturesubgroupofinfantacutelymphoblasticleukemia AT ogawaseishi multiomicsanalysisdefineshighlyrefractoryrasburdenedimmaturesubgroupofinfantacutelymphoblasticleukemia AT takitajunko multiomicsanalysisdefineshighlyrefractoryrasburdenedimmaturesubgroupofinfantacutelymphoblasticleukemia |